Quadriga Capital
Quadriga Capital describes itself as a partner to mid-market growth companies in Germany, Austria, Switzerland, and neighboring countries. Its stated core sectors are Healthcare, Tech-Enabled Services, and Smart Industries, with target sales of EUR 50 million to EUR 300 million, company values of EUR 50 million to EUR 250 million, and equity investments of EUR 20 million to EUR 120 million.
Quadriga Capital publicly targets established, medium-sized growth companies led by entrepreneurial management teams.
It primarily pursues majority stakes, with qualified minority stakes in exceptional circumstances, and identifies succession solutions, carve-outs, management buy-outs and buy-ins, consolidation strategies, public-to-private transactions, and growth financing as investment situations.[1][2][3][4][5][8][9]
What does Quadriga Capital invest in?
Quadriga Capital is operated by Quadriga Capital Eigenkapitalberatung GmbH, located in Frankfurt, Germany. The firm describes itself as a partner to mid-market growth companies in Germany, Austria, Switzerland, and neighboring countries.
Quadriga Capital provides equity capital through its funds and supports portfolio-company growth through operational excellence, digital transformation, internationalization, and organic or acquisition-led expansion. The firm states that its funds have arranged and assisted on investments in more than 150 mid-market growth companies.[1][2][3]
Quadriga Capital focuses on long-term, responsible, value-creating investments in promising mid-market growth companies. It describes a strategy of developing market leaders organically or through buy-and-build acquisitions.
The firm also states that its funds support international expansion into the United States, South America, and Asia. Its sustainability approach includes ESG and impact integration across the investment lifecycle, including external ESG due diligence, post-acquisition roadmaps, active ownership, and monitoring during the holding period.[2][3][8]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Quadriga Capital?
An owner evaluating Quadriga Capital can compare the company’s stated DACH-region focus, sector coverage, size parameters, control preference, and identified transaction situations with the characteristics of the proposed process. The public criteria point to established mid-market growth companies and primarily majority investments, while the firm also identifies qualified minority investments in exceptional circumstances.
Owners should clarify which current fund and legal entity would make the investment, how the stated equity-capital and company-value ranges apply to the opportunity, and whether the proposed structure would be a majority or exceptional minority investment. They should also ask how Quadriga would approach digital transformation, operational improvement, internationalization, buy-and-build activity, ESG diligence, and ownership-horizon planning for the specific situation.[3][8]
How would the stated EUR 50 million to EUR 250 million company-value range and EUR 20 million to EUR 120 million equity-capital range apply to this opportunity
Does Quadriga Capital require majority control for this situation, and what structure would apply if the opportunity were considered as an exceptional minority investment
What companies does Quadriga Capital target?
Quadriga Capital seeks established, medium-sized growth companies led by entrepreneurial management teams. It publicly states a target sales-volume range of EUR 50 million to EUR 300 million, target company values of EUR 50 million to EUR 250 million, and equity-capital investments of EUR 20 million to EUR 120 million.
The firm primarily pursues majority stakes, while qualified minority stakes may be considered in exceptional circumstances.[3]
Quadriga Capital identifies Healthcare, Tech-Enabled Services, and Smart Industries as its core sectors.[3]
Quadriga Capital funds invest primarily in Germany, Austria, Switzerland, and neighboring countries, described by the firm as the DACH region and surrounding markets. The firm also states that it has supported international expansion into the United States, South America, and Asia.[2][3]
Quadriga Capital’s stated model includes developing companies organically or through buy-and-build acquisitions. Its public materials also describe support for organic or acquisition-led expansion, alongside operational improvement, digital transformation, and internationalization.
The sources cited for this profile do not establish specific add-on approval processes, financing parameters, or integration requirements.[3]
Publicly identified examples include United Therapy’s acquisition of a majority stake in VITA Group, dated March 20, 2026; Quadriga Capital-backed GBA Group’s acquisition of a majority stake in Johner Institut GmbH, dated March 10, 2026; and salestech group’s investment in ILI.DIGITAL, dated July 22, 2025.
Quadriga Capital Funds also announced the sale of Kinetics Group to Exyte on April 16, 2024. The official references page presents selected previous references but does not publish a complete portfolio chronology or transaction-level financial terms on that page.[4][5][6][7][9]
Recent official announcements identify several transactions involving Quadriga Capital-backed companies. United Therapy’s acquisition of a majority stake in VITA Group was dated March 20, 2026. GBA Group’s acquisition of a majority stake in Johner Institut GmbH was dated March 10, 2026. Salestech group’s investment in ILI.DIGITAL was dated July 22, 2025.
On April 16, 2024, Quadriga Capital Funds announced the sale of Kinetics Group to Exyte. The cited United Therapy and Johner Institute announcements do not disclose purchase price, enterprise value, equity consideration, or financing terms.[4][5][6][7]
What is not clear from Quadriga Capital's public investment criteria?
The cited United Therapy transaction announcement does not disclose the purchase price, enterprise value, equity consideration, or financing terms for the VITA Group transaction. The cited Johner Institute transaction announcement likewise does not disclose those terms for the majority-stake acquisition.
The official references page presents selected previous references but does not publish a complete portfolio chronology or transaction-level financial terms on that page.[4][5][9]
Questions to ask when evaluating Quadriga Capital as a buyer or investment partner
Which current fund and legal entity would make the investment?
How would the stated EUR 50 million to EUR 250 million company-value range and EUR 20 million to EUR 120 million equity-capital range apply to this opportunity?
Does Quadriga Capital require majority control for this situation, and what structure would apply if the opportunity were considered as an exceptional minority investment?
Which operating capabilities would support digital transformation, operational improvement, internationalization, or add-on acquisitions?
What ESG, impact, diligence, and reporting requirements would apply to the proposed investment?
How would the proposed transaction be characterized among succession, carve-out, management-led, consolidation, public-to-private, or growth-financing situations?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Services / capabilities
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Investment approach
- Public disclosure information
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.